Александрович О. В., Озерова И. Н., Перова Н. В., Метельская В. А., Олферьев А. М., Щукина Г. Н. Взаимосвязь инсулинорезистентности и показателей липид-транспортной системы при нормогликемии натощак. Кардиоваскулярная терапия и профилактика. 2007;6(5):64-69.
1. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2000; 24: 89-94.
2. Jensen CC, Cnop M, Hull RL, et al. β-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 2002; 51: 2170-8.
3. McAuley KA, Williams SM, Mann JI, et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001: 24(3): 460-4.
4. Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation 2000; 101: 975-80.
5. Evans M, Khan N, Rees A. Diabetic dyslipidaemia and coronary heart disease: new perspectives. Curr Opin Lipidol 1999; 10(5): 387-91.
6. Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005; 28(10): 2472-9.
7. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124(Suppl): S11-20.
8. Lewis GF, Rader DJ. New Insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-32.
9. Yancey PG, Bortnic AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23: 712-9.
10. Rye K-A, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004; 24: 421-8.
11. Rashid Sh, Patterson BW, Lewis GF. Thematic review series: patient-oriented research. What have we learned about HDL metabolism from kinetic studies in humans? J Lipid Res 2006; 47(8): 1631-42.
12. Rye K-A, Clay MA, Barter PJ. Remodeling of high density lipoproteins by plasma factors. Atherosclerosis 1999; 145: 227- 38.
13. Cheung M, Sihley Sh, Palmer JP, et al. Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-II). J Lipid Res 2003; 44: 1552-8.
14. Lamarch B, Uffelman KD, Carpentier A, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance o HDL apo A-I in healthy men. J Clin Invest 1999; 103: 1191-9.
15. Asztalos BF, Rohein PS, Milani RL, et al. Distribution of apo A-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 2670-6.
16. Borggreve SE., De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33(12): 1051-69.
17. Tu AY, Albers JJ. Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 2001; 50(8): 1851-6.
18. Svannborg A, Svennercholm L. Plasma total lipid cholesterol, triglycerides, phosphlipids and free fatty acids in a healthy scandinavian population. Acta Med Scand 1961; 169: 43-6.
19. de la Llera Moya M, Atger V, Paul JL, et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux; relations between serum components and efflux, esterification and transfer. Arterioscler Thromb 1994; 14: 1056- 65.
20. Wallace NM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.
21. Соколов Е.И., Александрович О.В., Щельцына Н.В. и др. Субфракционный спектр ЛПНП при абдоминальном и глютеофеморальном ожирении. Бюлл экспер биол мед 2003;11: 513-5.
22. Ooi EM, Watts GF, Ji J, et al. Plasma phospholipid transfer protein activity, a determinant of HDL kinetics in vivo. Clin Endocrinol 2006; 65(6): 752-9.
23. Александрович О.В., Озерова И.Н., Олферьев А.М. и др. Ассоциация уровня аполипопротеина А II сыворотки крови с комбинированной гиперлипидемией и нарушенной толерантностью к глюкозе. Бюлл экспер биол мед 2006; 6: 625-8.
24. Syvanne M, Castro G, Dengremont C, et al. Cholesterol efflux Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of Lp A-I:A-II particles and phospholipid tranfer protein. Atherosclerosis 1996; 127: 245-53.
25. Huuskonen J, Olkkonen VM, Jauhiainen M, et al. The impact of phospholipid tranfer protein (PLTP) on HDL metabolism. Atherosclerosis 2001; 155: 269-81.
26. Dullaart RP, van Tol A. Role of phospholipids transfer protein and prebeta-high density lipoproteins in maintaining cholesterol efflux from Fu5AH cells to plasma from insulin-resistant subjects. Scand J Clin Lab 2001; 61(1): 69-74.
27. Boucher J, Ramsamy TA, Braschi S, et al. Apolipoprotein A II regulates HDL stability and affects hepatic lipase association and activity. J Lipid Res 2004; 45: 849-58.
28. Rye K-A, Wee K, Curtiss LK, et al. Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation. J Biol Chem 2003; 278: 22530-6.
29. Caiazza D, Jahangiri A, RaderDJ, et al. Apolipoproteins regulate the kinetics of endothelial lipase-mediated hydrolysis of phospholipids in reconstituted high-density lipoproteins. Biochemistry 2004; 43: 11898-905.
30. Hime NJ, Barter PJ, Rye K-A. The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol. J Biol Chem 1998; 273(42): 27191-8.
